Autonomix Medical (AMIX) shares were up more than 10% in recent premarket activity Thursday after the medical device company said the US Patent and Trademark Office had granted it a patent for its proprietary catheter-based technology used to collect and process sensing data for real-time physiological monitoring.
The company said the broad applications for the technology include heart mapping, arterial mapping, parenchymal monitoring, central nervous system monitoring, and implant, robotic and wearable precision applications.
Autonomix Medical said it expects to file an investigational device exemption with the US Food and Drug Administration.
The company also said it aims to begin US clinical trials this year in support of a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the US to treat pancreatic cancer pain.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。